Correction to: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT (Bone Marrow Transplantation, (2024), 59, 6, (832-837), 10.1038/s41409-024-02251-0)

Publikation: Spezielle Publikationen/BeiträgeKorrekturen (Errata und Widerrufe)Begutachtung

Beitragende

  • Anna Sureda - , Catalan Institute of Oncology (ICO), Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Universitat de Barcelona (Autor:in)
  • Paul A Carpenter - , Fred Hutchinson Cancer Research Center (Autor:in)
  • Andrea Bacigalupo - , Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Autor:in)
  • Vijaya Raj Bhatt - , University of Nebraska Medical Center (Autor:in)
  • Josu de la Fuente - , Imperial College London (Autor:in)
  • Aloysius Ho - , Singapore General Hospital, National Cancer Centre (Autor:in)
  • Leslie Kean - , Dana-Farber Cancer Institute (Autor:in)
  • Jong Wook Lee - , Catholic University of Korea (Autor:in)
  • Isabel Sánchez-Ortega - , European Society for Blood and Marrow Transplantation Paris (Autor:in)
  • Bipin N Savani - , Vanderbilt University Medical Center (Autor:in)
  • Johannes Schetelig - , Medizinische Klinik und Poliklinik I (Autor:in)
  • Edward A Stadtmauer - , University of Pennsylvania Perelman School of Medicine (Autor:in)
  • Yoshiyuki Takahashi - , Nagoya University (Autor:in)
  • Yoshiko Atsuta - , Aichi Medical University (Autor:in)
  • John Koreth - , Dana-Farber Cancer Institute (Autor:in)
  • Nicolaus Kröger - , Universitätsklinikum Hamburg-Eppendorf (UKE) (Autor:in)
  • Per Ljungman - , Karolinska-Universitätskrankenhaus (Autor:in)
  • Shinichiro Okamoto - , Keio University (Autor:in)
  • Uday Popat - , University of Texas MD Anderson Cancer Center (Autor:in)
  • Robert Soiffer - , Dana-Farber Cancer Institute (Autor:in)
  • Heather E Stefanski - , Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, USA. (Autor:in)
  • Mohamed A Kharfan-Dabaja - , Mayo Clinic Jacksonville, FL (Autor:in)

Abstract

Correction to: Bone Marrow Transplantationhttps://doi.org/10.1038/s41409-024-02251-0, published online 5 March 2024 The Funding information section was missing from this article and should have read: CIBMTR is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research. Support is also provided by the Medical College of Wisconsin, NMDP, Gateway for Cancer Research, Pediatric Transplantation and Cellular Therapy Consortium and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Alexion; Allogene; AlloVir, Inc.; Amgen, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; BeiGene; BioLineRX; Blue Spark Technologies; bluebird bio, inc.; Blueprint Medicines; Bristol Myers Squibb Co.; CareDx Inc.; CSL Behring; CytoSen Therapeutics, Inc.; DKMS; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gift of Life Biologics; Gift of Life Marrow Registry; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karius; Kashi Clinical Laboratories; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Labcorp; Legend Biotech; Mallinckrodt Pharmaceuticals; Med Learning Group; Merck & Co.; Mesoblast; Millennium, the Takeda Oncology Co.; Miller Pharmacal Group, Inc.; Miltenyi Biotec, Inc.; MorphoSys; MSA-EDITLife; Neovii Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; OriGen BioMedical; Ossium Health, Inc.; Pfizer, Inc.; Pharmacyclics, LLC, An AbbVie Company; PPD Development, LP; REGiMMUNE; Registry Partners; Rigel Pharmaceuticals; Sanofi; Sarah Cannon; Seagen Inc.; Sobi, Inc.; Stemcell Technologies; Stemline Technologies; STEMSOFT; Takeda Pharmaceuticals; Talaris Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; WellSky; Xenikos BV. The original article has been corrected.

Details

OriginalspracheEnglisch
Seiten1335
Seitenumfang1
Band59
Ausgabenummer9
FachzeitschriftBone marrow transplantation
PublikationsstatusVeröffentlicht - Sept. 2024
Peer-Review-StatusJa
No renderer: customAssociatesEventsRenderPortal,dk.atira.pure.api.shared.model.researchoutput.ContributionToPeriodical

Externe IDs

PubMedCentral PMC11368801
Scopus 85196521768
Mendeley 0f00df4a-70a8-377f-b31f-e3c12d1c5805

Schlagworte

Ziele für nachhaltige Entwicklung